"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 5 | 7 |
| 2011 | 2 | 6 | 8 |
| 2012 | 6 | 6 | 12 |
| 2013 | 4 | 8 | 12 |
| 2014 | 7 | 10 | 17 |
| 2015 | 11 | 4 | 15 |
| 2016 | 11 | 13 | 24 |
| 2017 | 9 | 13 | 22 |
| 2018 | 16 | 10 | 26 |
| 2019 | 12 | 6 | 18 |
| 2020 | 18 | 17 | 35 |
| 2021 | 18 | 22 | 40 |
| 2022 | 6 | 39 | 45 |
| 2023 | 2 | 36 | 38 |
| 2024 | 13 | 12 | 25 |
| 2025 | 6 | 15 | 21 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. J Infect Dis. 2025 Oct 15; 232(4):971-981.
-
Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations. Sci Adv. 2025 Sep 12; 11(37):eadx3505.
-
Structural elucidation of a unique binding mode by an intact alphavirus human IgG molecule to a quaternary epitope. Nat Commun. 2025 Aug 19; 16(1):7716.
-
Identification of the seven critical residues that control ZIKV-DENV cross-reactivity to engineer a non-cross-reactive ZIKV vaccine. Cell Rep. 2025 Aug 26; 44(8):116098.
-
Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life. Nature. 2025 Sep; 645(8082):1020-1028.
-
Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials. PLoS Med. 2025 Jul; 22(7):e1004616.
-
Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses. Nat Commun. 2025 Jul 01; 16(1):5702.
-
Infant Antibodies After Maternal COVID-19 Vaccination During Pregnancy or Postpartum. Pediatrics. 2025 Jul 01; 156(1).
-
Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. PLoS One. 2025; 20(6):e0325561.
-
Pan-H7 influenza human antibody virus neutralization depends on avidity and steric hindrance. JCI Insight. 2025 Jul 08; 10(13).